Journal of Oncology / 2019 / Article / Fig 2

Research Article

Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program

Figure 2

The efficacy of vemurafenib (PLX) and trametinib (TRA) in patient-derived melanoma cell lines. (a) The influence of vemurafenib and trametinib on p-ERK1/2 and p-MEK1/2 levels was assessed by immunoblotting. GAPDH was used as loading control. The proteins were visualized by using ChemiDoc Imaging System (Biorad). The images are cropped, which is indicated by white spaces. (b) Changes in viable cell number were assessed after 1, 2, and 3 days of treatment using acid phosphatase activity assay. Data represent the average values from a typical experiment conducted in triplicate.


We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.